Disclosed Amino Acid Sequence Derived From Parasitic Organism (e.g., Dirofilaria, Eimeria, Trichinella, Etc.) Patents (Class 424/191.1)
-
Publication number: 20150037365Abstract: The present invention provides a vaccine for preventing and/or treating Plasmodium falciparum infections, which comprises a polypeptide set forth in SEQ ID NO: 1 or represented by formula (1), and an adjuvant. X1-A-B-X2-Y-X3-(Y)n-X4-(Y)n-X5??(1) (In the formula, X1 represents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; X2 represents the 73th to 177th amino acid residues; X3 represents the 178th to 258th amino acid residues; X4 represents the 259th to 289th amino acid residues; X5 represents the 290th to 334th amino acid residues; A represents an 8-mer repeat sequence contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; B represents a sequence of a serine-rich region contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; Y represents any one selected from A-A, A-B, and B; and n is an integer of 0 or 1.Type: ApplicationFiled: July 8, 2014Publication date: February 5, 2015Inventors: Toshihiro HORII, Ken ISHII, Takahiro TOUGAN
-
Publication number: 20150017200Abstract: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.Type: ApplicationFiled: May 23, 2014Publication date: January 15, 2015Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Ajay BHATIA, Steven G. REED
-
Publication number: 20150004099Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: ApplicationFiled: February 8, 2013Publication date: January 1, 2015Applicant: VAR2 PHARMACEUTICALS APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Publication number: 20140377299Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore.Type: ApplicationFiled: August 4, 2014Publication date: December 25, 2014Applicant: LIFE SCIENCES RESEARCH PARTNERS VZWInventor: Jean-Marie SAINT-REMY
-
Patent number: 8916167Abstract: The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula Ab-X where the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.Type: GrantFiled: March 12, 2013Date of Patent: December 23, 2014Assignee: Purdue Research FoundationInventors: Philip S. Low, Mary J. Turk
-
Patent number: 8911746Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.Type: GrantFiled: March 12, 2013Date of Patent: December 16, 2014Assignee: Infectious Disease Research InstituteInventors: Yasuyuki Goto, Steven G. Reed
-
Publication number: 20140356391Abstract: Polypeptides comprising amino acid sequences of particulate antigens isolated from various species of Leishmania protozoa, or immunogenic variants thereof, are disclosed for the treatment and clinical remission of cutaneous leishmaniasis, psoriasis, psoriatic arthritis, rheumatoid arthritis, atopic dermatitis, seborrheic dermatitis and skin papilloma. Also disclosed are nucleic acid sequences encoding such polypeptides, vectors incorporating such nucleic acid sequences, methods for genetically engineering microbial host cells to produce such polypeptides, and such recombinant microbial host cells. The polypeptides induced a TH1 cellular immune response, a positive intradermic reaction, and a blastogenic response in peripheral blood lymphocytes after clinical remission of lesions.Type: ApplicationFiled: May 29, 2013Publication date: December 4, 2014Inventor: Jose Antonio O'Daly
-
Publication number: 20140348870Abstract: Contemplated compositions and methods employ selected antigens form Plasmodium falciparum and can be used as a vaccine, therapeutic agent, and/or diagnostic tool. Especially preferred antigens are post-challenge immunity associated antigens that are identified via pre-infection suppressive treatment, controlled sub-symptomatic infection to develop immunity, and comparative proteomic differential analysis.Type: ApplicationFiled: November 30, 2012Publication date: November 27, 2014Inventors: Philip L. Felgner, Xiaowu Liang, Robert Sauerwein
-
Publication number: 20140341918Abstract: The invention provides compositions and methods for preventing or reducing the severity of malaria.Type: ApplicationFiled: November 30, 2012Publication date: November 20, 2014Inventors: Jonathan Kurtis, Christian Parcher Nixon, Dipak Kumar Raj, Jennifer Frances Friedman, Michal Fried, Patrick Emmet Duffy
-
Publication number: 20140322257Abstract: The present invention refers to recombinant DNA molecules codifying fused peptides from different allergens from Blomia tropicalis and Dermatophagoides pteronyssinus having potential usefulness in prevention and treatment of allergies caused by domestic mites. Specifically, the invention discloses fusion proteins composed by different fragments of allergens Der p 1, Der p 2, Der p 7, Der p 8, Blo t 5, Blo t 8, Blo t 18, Blo t 12 and Blo t 13 with reduced serum IgE reactivity in allergic and non allergic individuals. It also discloses methods for production of these molecules in an expression system based on E. coli and purification. The invention refers also to effective and safe vaccines.Type: ApplicationFiled: September 20, 2012Publication date: October 30, 2014Applicant: UNIVERSIDAD DE CARTAGENAInventors: Leonardo Puerta Llerna, Luis Caraballo, José Fernando Cantillo
-
Publication number: 20140271656Abstract: Immunologically active agents are described, including isolated Pneumocystis A 12 protein or polypeptides; immunogenic conjugates containing Pneumocystis A 12 protein or polypeptide of the present invention; antibodies recognizing the Pneumocystis A 12 protein or polypeptide or the immunogenic conjugates of the present invention; and nucleic acid molecules that encode the Pneumocystis A 12 protein or polypeptide of the present invention, as well as DNA constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and DNA constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a Pneumocystis organism, in a subject.Type: ApplicationFiled: August 6, 2012Publication date: September 18, 2014Applicant: UNIVERSITY OF ROCHESTERInventors: Francis Gigliotti, Terry W. Wright, Constantine G. Haidaris, Patricia J. Simpson-Haidaris
-
Publication number: 20140271702Abstract: Compositions of either the aquaporin protein from the cattle tick, Rhipicephalus microplus, or a nucleic acid construct incorporating a nucleic acid sequence encoding this aquaporin protein, are effective for eliciting a protective immune response against other tick species in non-bovine animals. The R. microplus aquaporin protein is antigenic and can be administered as a protein vaccine, or in the alternative, the nucleic acid construct can be utilized as a DNA vaccine. Induction of the immune response significantly reduces or eliminates the infestation of treated, non-bovine animals with ticks other than the cattle tick, particularly the brown dog tick, Rhipicephalus sanguineus. Moreover, as ticks are vectors of a variety of pathogenic agents, the reduction in the incidence of tick infestation afforded by the vaccines may concurrently reduce the incidence of diseases caused by these pathogenic agents in susceptible animals.Type: ApplicationFiled: March 7, 2014Publication date: September 18, 2014Inventors: Felicito Guerrero, Adalberto A. Perez De Leon, Lane D. Foil
-
Publication number: 20140255441Abstract: This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a TLR5 agonist on the exterior without an antigen.Type: ApplicationFiled: July 31, 2012Publication date: September 11, 2014Applicants: CHILDREN'S HEATLHCARE OF ATLANTA, INC., EMORY UNIVERSITYInventors: Richard W. Compans, Baozhong Wang, Martin L. Moore, Fu Shi Quan
-
Patent number: 8821886Abstract: Recombinant protein of the catalytic subunit of the phosphatase Serine/threonine protein of Angiostrongylus costarricensis, and active peptides used in the production of an intranasal anthelmintic vaccine.Type: GrantFiled: February 19, 2009Date of Patent: September 2, 2014Assignee: Universidad de GranadaInventors: Antonio Osuna Carrillo de Albornoz, Miguel Burgos Poyatos, Jennifer Solano Parada, Fatima Brazil Dos Santos
-
Patent number: 8808712Abstract: The present invention provides a vaccine for preventing and/or treating Plasmodium falciparum infections, which comprises a polypeptide set forth in SEQ ID NO: 1 or represented by formula (1), and an adjuvant. X1-A-B-X2-Y-X3-(Y)n-X4-(Y)n-X5??(1) (In the formula, X1 represents the 1st to 7th amino acid residues in a polypeptide set forth in SEQ ID NO: 1; X2 represents the 73th to 177th amino acid residues; X3 represents the 178th to 258th amino acid residues; X4 represents the 259th to 289th amino acid residues; X5 represents the 290th to 334th amino acid residues; A represents an 8-mer repeat sequence contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; B represents a sequence of a serine-rich region contained in a 47-kd region of SERA polypeptide of Plasmodium falciparum; Y represents any one selected from A-A, A-B, and B; and n is an integer of 0 or 1.Type: GrantFiled: April 30, 2010Date of Patent: August 19, 2014Assignee: Osaka UniversityInventors: Toshihiro Horii, Ken Ishii, Takahiro Tougan
-
Patent number: 8809494Abstract: Isolated proteins and nucleic acid sequence encoding such protein that interacts with a red blood cell to be invaded by a malaria parasite and link with a component of the actin-myosin based machinery of the malaria parasite are provided. In addition methods for identifying agents which inhibit the function of these proteins as chemotherapeutic and/or immunologic agents for treatment and prevention of malaria infections are provided. Compositions for treatment and prevention of malaria infections and methods for preventing and treating malaria infections are also provided.Type: GrantFiled: November 17, 2005Date of Patent: August 19, 2014Assignee: Drexel UniversityInventors: Lawrence W. Bergman, Akhil B. Vaidya
-
Publication number: 20140212452Abstract: Two antigenic and immunogenic proteins of the cattle tick, Rhipicephalus microplus, and the genes encoding these proteins, are effective for eliciting a protective immune response that controls and prevents infestations of bovines and other livestock by the tick. The proteins isolated from the cattle tick include an aquaporin protein and a TC5777 gut membrane protein. Each of the proteins elicit an immunoprotective response in livestock to the cattle tick, and can be formulated and administered as vaccines. Alternatively, the isolated DNA sequences which encode these proteins can be incorporated into nucleic acid constructs which could be utilized as DNA vaccines. The nucleic acid constructs can also be used for the transformation of cells and the production of recombinant proteins. Induction of the protective immune response controls and prevents infestations of the treated animals with the tick, thereby protecting them against tick-borne pathogen transmission.Type: ApplicationFiled: March 20, 2014Publication date: July 31, 2014Inventors: Felicito Guerrero, Adalberto A. Perez de Leon
-
Patent number: 8784832Abstract: The disclosure provides compositions that are useful for eliciting a strain-transcending immune response in an animal or human directed against the blood-stage of the malarial parasite Plasmodium vivax. The compositions are based on the ligand domain of Plasmodium vivax Duffy binding protein (PvDBPII). Polar charged polymorphic residues within the dominant strain-specific B-cell epitope were mutated to uncharged residues (e.g. serine, alanine and threonine). This DEKnull variant of PvDBPII produced in bacteria can be purified and refolded in vitro to mimic conformation and erythrocyte binding function of native DBPII. Immunogenicity of DEKnull was confirmed by administration to mice. Compared to the naturally-occurring, strain variant DBPII, DEKnull elicits antibodies that are more broadly reactive with different strain variants of DBPII and enhances production of functional inhibitory antibodies to the shared protective epitopes of native DBPII.Type: GrantFiled: August 20, 2012Date of Patent: July 22, 2014Assignee: University of South Florida (A Florida Non-Profit Corporation)Inventors: John H. Adams, Francis B. Ntumngia, Jesse L. Schloegel, Samantha J. Barnes, Amy M. McHenry, Patchanee Chootong
-
Publication number: 20140193452Abstract: The invention relates to nucleic acid constructions, characterized in that they comprise nucleic acids which are isolated in the sense position and which are capable of coding for an immunogenic protein of promastigotes or amastigotes of Leishmania, said nucleic acids responding to one of the sequences SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 et SEQ ID NO:11 and coding for a protein respectively exhibiting a sequence SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10 et SEQ ID NO:12. The invention can be used for over-expression of the genes of Leishmania coding for an excretion/secretion antigen.Type: ApplicationFiled: November 4, 2013Publication date: July 10, 2014Inventors: JEAN-LOUP LEMESRE, MIREILLE CAVALEYRA, DENIS SERENO, PHILIPPE HOLZMULLER
-
Patent number: 8765146Abstract: The invention provides adenoviral vectors comprising an adenoviral genome comprising heterologous antigen-encoding nucleic acid sequences, such as Plasmodium nucleic acid sequences, operably linked to promoters. The invention further provides a method of inducing an immune response against malaria in a mammal comprising administering the adenoviral vectors to the mammal.Type: GrantFiled: August 31, 2006Date of Patent: July 1, 2014Assignees: GenVec, Inc., The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary of the NavyInventors: Joseph T. Bruder, Imre Kovesdi, C. Richter King, Duncan L. McVey, Damodar R. Ettyreddy, Denise Louise Doolan, Daniel John Carucci
-
Publication number: 20140170182Abstract: The present invention relates to a method for the production of correctly folded Pfs48/45. This is achieved in the lactococcus lactis when Pfs48/45 or fractions thereof are fused genetically to a glutamate rich protein, e.g. GLURP from Plasmodium falciparum.Type: ApplicationFiled: October 3, 2012Publication date: June 19, 2014Applicant: STATENS SERUM INSTITUTInventors: Michael Theisen, Gorm Andersen
-
Patent number: 8747869Abstract: The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.Type: GrantFiled: March 19, 2011Date of Patent: June 10, 2014Assignee: Massachusetts Institute of TechnologyInventors: Darrell J. Irvine, Jaehyun Moon
-
Patent number: 8741305Abstract: The present invention relates to a protein composition suitable for inducing an immune response in a vertebrate comprising 2 to 10 protein variants of a single antigen, which is the APICAL MEMBRANE ANTIGEN 1 (PfAMA1 OR AMA1) of a Plasmodium species. The antigen comprises a plurality of variable amino acid positions, wherein the amino acid sequences of said protein variants, in combination, represent both the frequency of occurrence of each amino acid at said variable amino acid positions and the linkage between the variable amino acid positions, and wherein said frequency of occurrence is at least between 10% to 20% such as 10%, 11%, 12%, 13%, . . . , 20% in the single antigen, and wherein at least 75% of the linkages between the variable amino acid position is presented by the combination of protein variants.Type: GrantFiled: December 21, 2006Date of Patent: June 3, 2014Assignee: Stichting Biomedical Primate Research CentreInventors: Alan William Thomas, Clemens Hendricus Martinus Kocken, Bart Willem Faber, Edmond Joseph Remarque
-
Patent number: 8722063Abstract: Two antigenic and immunogenic proteins of the cattle tick, Rhipicephalus microplus, and the genes encoding these proteins, are effective for eliciting a protective immune response that controls and prevents infestations of bovines and other livestock by the tick. The proteins isolated from the cattle tick include an aquaporin protein and a TC5777 gut membrane protein. Each of the proteins elicit an immunoprotective response in livestock to the cattle tick, and can be formulated and administered as vaccines. Alternatively, the isolated DNA sequences which encode these proteins can be incorporated into nucleic acid constructs which could be utilized as DNA vaccines. The nucleic acid constructs can also be used for the transformation of cells and the production of recombinant proteins. Induction of the protective immune response controls and prevents infestations of the treated animals with the tick, thereby protecting them against tick-borne pathogen transmission.Type: GrantFiled: May 24, 2012Date of Patent: May 13, 2014Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Felicito Guerrero, Jr., Adalberto A. Perez de Leon
-
Patent number: 8722332Abstract: The invention relates to a method for determining the responsiveness of a Dirofilaria spp. nematode to a macrocyclic lactone, by determining the genotype of the nematode at a position in a P-glycoprotein gene of the nematode corresponding to position 11, and optionally to position 618, in SEQ ID NO: 1, wherein the genotype GG at a position corresponding to position 11, or at positions corresponding to positions 11 and 618, in SEQ ID NO: 1 indicates that the nematode is likely resistant to the macrocyclic lactone. The invention also relates to methods for selecting a treatment to treat an animal infected with macrocyclic lactone resistant Dirofilaria spp nematode, and treating the animal; or for selecting a prophylactic to prevent an animal from becoming infected with a macrocyclic lactone resistant Dirofilaria spp nematode, and providing the prophylactic to the animal. The invention further relates to an isolated nucleic acid having at least 80% sequence identity to SEQ ID NO: 1.Type: GrantFiled: March 30, 2011Date of Patent: May 13, 2014Assignees: The Royal Institution for the Advancement of Learning/McGill University, Novartis AGInventors: Roger Prichard, Catherine Bourguinat, Timothy Geary, Rudolf Schenker
-
Patent number: 8710009Abstract: The present invention compositions and methods of using at least a portions of an isolated and purified ?-crystallin polypeptide that includes one or more ?-pleated sheets and that prevents neurotoxicity and amyloidogenesis.Type: GrantFiled: May 26, 2005Date of Patent: April 29, 2014Assignee: The Texas A&M University SystemInventors: Allison Ficht, Theresa Good, Ken Carson, Sundmun Lee
-
Patent number: 8703147Abstract: The present invention provides compositions and methods useful in the treatment or prevention of a condition caused by or associated with infection by Plasmodium falciparum, such as malaria. The compositions include various antigens of Plasmodium falciparum, both alone and in combination. The invention further includes fragments of the antigens.Type: GrantFiled: November 5, 2008Date of Patent: April 22, 2014Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Alan Cowman, James Beeson, Alexander Gerd Maier, Kristina E. M. Persson, Jonathan S. Richards, Sash Lopaticki
-
Publication number: 20140093530Abstract: The present invention relates to a synthetic antigenic sequence which represents a combination of epitope-containing sequences from the highly polymorphic block 2 repeat region of K1-type Plasmodium falciparum merozite surface antigen (MSP1) and fusion proteins containing that sequence in combination with additional epitope-containing sequences capable of inducing antibody and cellular immune responses to P.Type: ApplicationFiled: October 9, 2013Publication date: April 3, 2014Inventors: Kevin TETTEH, David Conway
-
Publication number: 20140093531Abstract: Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.Type: ApplicationFiled: December 5, 2013Publication date: April 3, 2014Applicants: Fundacao Oswaldo Cruz (FIOCRUZ), The Government of the United States of America as represented by the Secretary of the Department ofInventors: Jesus G. Valenzuela, Jose M.C. Ribeiro, Aldina Barral, Manoel Netto, Claudia I. Brodskyn, Regis Gomes
-
Patent number: 8663649Abstract: Provided herein are vaccine compositions for control of Trypanosoma cruzi infection and Chagas disease. The compositions comprise plasmids encoding o GPI-anchored genes ASP-2, TcG-1, TcG2 and TcG4 from Trypanosoma cruzi; plasmids encoding cytokines IL12 and GM-CSF; and plasmids encoding a gene expression system. Certain vaccine compositions comprise recombinant proteins, selected from TcG-1, TcG2 and TcG4 from Trypanosoma cruzi. In another vaccination strategy, the recombinant proteins are replaced by lysates comprising Trypanosoma rangeli cells. Further provided herein are diagnosis compositions comprising 1) recombinant proteins, selected from TcG-1, TcG2 and TcG4 from Trypanosoma cruzi; 2) antibodies that specifically binds the TcG-1, TcG2 and TcG4 proteins; 3) sense and antisense polynucleotide sequences that encode the TcG-1, TcG2 and TcG4 proteins. Said compositions can be used in diagnosing and/or evaluating efficacy of treatments against Trypanosoma cruzi infection.Type: GrantFiled: July 11, 2011Date of Patent: March 4, 2014Assignee: The Board of Regents of the University of Texas SystemInventor: Nisha J. Garg
-
Patent number: 8629260Abstract: The present disclosure provides methods of selecting and uses of anti-arthropod vector vaccines to prevent Leishmaniasis. The present disclosure also provides compositions for vaccines to prevent Leishmaniasis.Type: GrantFiled: December 11, 2012Date of Patent: January 14, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Jesus G. Valenzuela, Yasmine Belkaid, Shaden Kamhawi, David Sacks, Jose M.C. Ribeiro
-
Publication number: 20140010816Abstract: The present invention relates to polypeptides from Plasmodium and polynucleotides encoding the polypeptides. The invention further relates to compositions comprising the polypeptides and their use in the treatment and prevention of malaria.Type: ApplicationFiled: November 8, 2011Publication date: January 9, 2014Inventors: Lin Chen, Alan Cowman, Tony Triglia
-
Publication number: 20140004141Abstract: Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen T. gondii and their use in various diagnostic tests, vaccines, and therapeutic agents. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.Type: ApplicationFiled: December 20, 2011Publication date: January 2, 2014Applicant: Immport Therapeutics, Inc.Inventors: David Huw Davies, Xiaowu Liang, Philip Felgner
-
Publication number: 20130323276Abstract: The present invention relates to polypeptides or fragments thereof for use as malaria vaccines. It also relates to nucleic acid molecules coding for the polypeptides of the invention. It further relates to compositions comprising such polypeptides or fragments thereof or the nucleic acid molecules, in particular combinations of such polypeptides or fragments thereof, and the use of such compositions as malaria vaccines.Type: ApplicationFiled: December 6, 2011Publication date: December 5, 2013Applicant: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Johannes Pfeil, Kirsten Heiss, Ann-Kristin Müller
-
Publication number: 20130323275Abstract: The present invention relates to methods of inducing a T-cell response against a Plasmodium species antigen in a subject. These method comprise administering to a subject a composition comprising a bacterium which expresses one or more immunogenic polypeptides, the amino acid sequence of which comprise one or more amino acid sequences derived from wild-type Plasmodium LSA1, Ce1TOS, CSP, and/or TRAP sequences, wherein said amino acid sequences are derived by (i) codon optimization of the wild-type sequence for expression in said bacterium, (ii) deletion of at least one hydrophobic region present in the wild-type sequence, and/or (iii) in the case of LSA1 and CSP, minimization of repeat units present in the wild-type sequence.Type: ApplicationFiled: October 10, 2011Publication date: December 5, 2013Applicant: ADURO BIOTECHInventors: Peter M. Lauer, Dirk G. Brockstedt, Thomas W. Dubensky
-
Publication number: 20130315947Abstract: Two antigenic and immunogenic proteins of the cattle tick, Rhipicephalus microplus, and the genes encoding these proteins, are effective for eliciting a protective immune response that controls and prevents infestations of bovines and other livestock by the tick. The proteins isolated from the cattle tick include an aquaporin protein and a TC5777 gut membrane protein. Each of the proteins elicit an immunoprotective response in livestock to the cattle tick, and can be formulated and administered as vaccines. Alternatively, the isolated DNA sequences which encode these proteins can be incorporated into nucleic acid constructs which could be utilized as DNA vaccines. The nucleic acid constructs can also be used for the transformation of cells and the production of recombinant proteins. Induction of the protective immune response controls and prevents infestations of the treated animals with the tick, thereby protecting them against tick-borne pathogen transmission.Type: ApplicationFiled: May 24, 2012Publication date: November 28, 2013Inventors: Felicito Guerrero, JR., Adalberto A. Perez de Leon
-
Publication number: 20130315945Abstract: Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed.Type: ApplicationFiled: March 12, 2013Publication date: November 28, 2013Applicant: GLOBEIMMUNE, INC.Inventor: Globelmmune, Inc.
-
Patent number: 8592556Abstract: The invention encompasses phage ?mru including phage induction, phage particles, and the phage genome. Also encompassed are phage polypeptides, as well as polynucleotides which encode these polypeptides, expression vectors comprising these polynucleotides, and host cells comprising these vectors. The invention further encompasses compositions and methods for detecting, targeting, permeabilising, and inhibiting microbial cells, especially methanogen cells, using the disclosed phage, polypeptides, polynucleotides, expression vectors, or host cells.Type: GrantFiled: September 25, 2008Date of Patent: November 26, 2013Assignee: Pastoral Greenhouse Research LimitedInventors: Eric Heinz Altermann, Graeme Trevor Attwood, Sinead Christine Leahy, William John Kelly, Robert Starr Ronimus, Dong Li, Zhanhao Kong, Linley Rose Schofield, Debjit Dey, Catherine Mary Tootill, Carrie Sang, Christina Diane Moon, Petrus Hendricus Janssen
-
Patent number: 8586709Abstract: Signal peptides and polypeptides from Methanobrevibacter ruminantium, a methanogenic archaea present in ruminants. Methods of using these peptides to permeabilise microbial cells, particularly M. ruminantium strain M1? (DSM 1093).Type: GrantFiled: September 25, 2008Date of Patent: November 19, 2013Assignee: Pastoral Greenhouse Research LimitedInventors: Graeme Trevor Attwood, William John Kelly, Eric Heinz Altermann
-
Patent number: 8574598Abstract: The invention relates to nucleic acid constructions, characterized in that they comprise nucleic acids which are isolated in the sense position and which are capable of coding for an immunogenic protein of promastigotes or amastigotes of Leishmania, said nucleic acids responding to one of the sequences SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5 et SEQ ID No. 11 and coding for a protein respectively exhibiting a sequence SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10 et SEQ ID No. 12. The invention can be used for over-expression of the genes of Leishmania coding for an excretion/secretion antigen.Type: GrantFiled: November 19, 2004Date of Patent: November 5, 2013Assignee: Institut de Recherche Pour le Developpement (IRD)Inventors: Jean-Loup Lemesre, Mireille Cavaleyra, Denis Sereno, Philippe Holzmuller
-
Publication number: 20130287786Abstract: The present invention relates to the field of veterinary parasitology, especially of canine Babesiosis. In particular the invention relates to a polypeptide being a novel canine Babesia antigen (CBA), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids. In particular the invention relates to the use of such components in vaccines against canine Babesiosis.Type: ApplicationFiled: December 28, 2011Publication date: October 31, 2013Inventors: Theodorus Petrus Maria Schetters, Karina Moubri-Menage, Jose Kleuskens, Andreas Walter Claudius Rohwer
-
Publication number: 20130287806Abstract: This invention discloses the use of Heminth Defense Molecules in methods and compositions for modulating immune responses including treating or preventing undesirable or deleterious immune responses.Type: ApplicationFiled: November 1, 2011Publication date: October 31, 2013Applicant: UNIVERSITY OF TECHNOLOGY, SYDNEYInventors: Sheila Donnelly, Mark William Robinson, John Pius Dalton, Joyce To
-
Publication number: 20130280290Abstract: The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a vaccine formulation as a purified protein and/or naked DNA, to induce an immune response in aquatic organisms against different ectoparasite species, including the known as sea lice, and pathogens associated with these infestations. The vaccine preparations, administered by oral route, immersion bath or injection, demonstrated its efficacy by producing IgM humoral immune response and reducing the number of parasites per fish in the vaccinated fishes.Type: ApplicationFiled: April 9, 2013Publication date: October 24, 2013Inventors: Yamila Carpio Gonzalez, Mario Pablo Estrada Garcia
-
Publication number: 20130273094Abstract: Vaccines are disclosed against parasites. The vaccines include peptides in an immunological composition. In particular, the parasite is Toxoplas gondii.Type: ApplicationFiled: November 3, 2011Publication date: October 17, 2013Applicants: THE UNIVERSITY OF CHICAGO, PAXVAX, INC., INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Rima McLeod, Tze Guan Tan, Jeffery L. Alexander, Hua Cong, William H. Witola, Kamal El Bissati, Ernest J. Mui, Steven G. Reed
-
Publication number: 20130273095Abstract: The present invention relates to the use of a peptide of P0 ribosomal protein in the manufacture of a vaccine composition to control of ectoparasite infestations and therefore the transmission of their associated pathogens. This peptide is located between 267 and 301 amino acids of the P0 protein, and can be obtained by recombinant means or by chemical synthesis. This peptide can be fused to a carrier protein or peptide, or an immuno-carrier and be included in an oily formulation. The formulations comprising the peptide vaccine confer protection against ticks and ectoparasites known as “sea lice” without generating autoimmunity in the host organism. Among these ticks may be mentioned species as Rhipicephalus microplus, Rhipicephalus sanguineus and Ixodes scapularis, and between sea lice are those of the Caligus and Lepeophtheirus genera.Type: ApplicationFiled: September 26, 2011Publication date: October 17, 2013Applicant: CENTRO DE INGENIERIA GENETICA BIOTECNOLOGIAInventors: Alina Rodriguez Mallon, Erlinda Fernández Díaz, Mario Pablo Estrada Garcia, Yamila Carpio González
-
Publication number: 20130259890Abstract: The present invention provides novel nucleotide sequence and other constructs used for expression of novel recombinant P. falciparum circumsporozoite proteins in bacterial cells such as E. coli. Processes are provided for producing a soluble recombinant P. falciparum CSP from E. coli. Methods to produce a human-grade, highly immunogenic anti-malaria vaccine based on CSP are shown. The novel recombinant P. falciparum circumsporozoite protein by itself or in combination with other malaria antigens or adjuvants can form the basis of an effective malaria vaccine.Type: ApplicationFiled: October 18, 2011Publication date: October 3, 2013Inventor: Sheetij Dutta
-
Publication number: 20130251740Abstract: The present invention relates to immunogenic agents based on trypanosomes, related compositions, and related methods.Type: ApplicationFiled: September 19, 2011Publication date: September 26, 2013Applicant: ROCKEFELLER UNIVERSITY (THE)Inventors: Fotini Papavasiliou, Pete Stavropoulos
-
Publication number: 20130236490Abstract: The present invention is a multivalent vaccine for immunizing an animal against filariasis. In some embodiments, the antigens of the multivalent vaccine are protein-based, DNA-based, or a combination thereof.Type: ApplicationFiled: November 7, 2011Publication date: September 12, 2013Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventor: Ramaswamy Kalyanasundaram
-
Publication number: 20130230551Abstract: Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against an a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed.Type: ApplicationFiled: December 20, 2012Publication date: September 5, 2013Inventors: Bin Wang, Huali Jin, Youmin Kang, Hsien-Jue Chu, Terry Kaleung NG
-
Publication number: 20130216569Abstract: The present invention provides a polypeptide comprising the amino acid sequence as shown as SEQ ID No. 1 or a homologue or fragment thereof, a nucleic acid capable of encoding such a polypeptide and a vaccine comprising such a polypeptide/nucleic acid. The vaccine may be used for the treatment and/or prevention of a disease associated with an apicomplexan parasite.Type: ApplicationFiled: August 2, 2011Publication date: August 22, 2013Applicant: THE PIRBRIGHT INSTITUTEInventors: Damer Blake, Adrian Smith, Martin Shirley